it seems that all prostate cancer patients with localized tumor(s) with Intermediate Risk should receive the ArteraAI test to prognosticate/predict how ADT would impact 5, 10, 15 years metastasis. It seems about 2/3 of these patients do not receive any added benefit from ADT therapy.
There are many tests to provide more understanding on a patients prostate cancer that can help determine appropriate treatment modalities. Patients should learn about all available tests and insist they receive them. (Decipher, Artera, Prostox, PSMA, etc. )